Pharmacokinetics of Tildrakizumab (MK ‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

Basic&Clinical Pharmacology&Toxicology, EarlyView.

Source: Basic and Clinical Pharmacology and Toxicology - April 20, 2018 Category: Drugs & Pharmacology Authors: Sauzanne Khalilieh , Peter Hodsman , Christine Xu , Anjela Tzontcheva , Shirley Glasgow , Diana Montgomery Source Type: research